For instance, EGFR, ALK, and ROS1 tyrosine kinase inhibitors against tumors with EGFR mutations, ALK fusions, and ROS1 fusions respectively, are already in use as standard treatments in lung cancer in clinical settings [28]. Here, EGFR is linked to lung carcinoma.